COPENHAGEN, September 13 /PRNewswire/ --

- Summary: Genmab Reveals That HuMax-Inflam Target is IL-8 and Future
Development Will be in Cancer and Inflammation

Genmab A/S (OMX: GEN) announced today its fully human HuMax-Inflam(TM)
antibody is directed to IL-8 (interleukin-8) and may have potential
application in oncology and inflammation. Genmab will initially focus on
studies to treat glioblastoma, a cancer of the central nervous system. Other
possible indications include chronic obstructive pulmonary disease (COPD) and
pustular dermatoses. In pre-clinical studies, HuMax-Inflam has been shown to
inhibit tumor growth in tumor models using primary human tumors in
immunodeficient mice. HuMax-Inflam was also effective in reducing disease
activity in palmoplantar pustulosis patients in a clinical study.

Genmab is currently preparing an improved commercially viable cell line
for HuMax-Inflam and hopes to start the next phase of clinical trials in
2008.

"Genmab's development plans for HuMax-Inflam have been a closely guarded
secret for several years now and we are happy to announce the solution to the
mystery, which has been much anticipated by the investment community," said
Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We believe that
HuMax-Inflam may have potential to treat patients with glioblastoma, which
has a very low survival rate."

About HuMax-Inflam and IL-8

HuMax-Inflam is a high affinity fully human IgG1,k antibody directed
towards IL-8. IL-8 is a major mediator of inflammation, a potent
chemoattractant for white blood cells called neutrophils, as well as an
important factor in angiogenesis. HuMax-Inflam effectively blocks binding of
IL-8 to neutrophils and inhibits neutrophils from migrating towards sites of
inflammation via a process known as chemotaxis. HuMax-Inflam also potently
inhibits IL-8 induced neutrophil activation. In pre-clinical studies,
HuMax-Inflam has been shown to inhibit tumor growth in tumor models using
primary human tumors in immunodeficient mice.

Results from a Phase I/II study of HuMax-Inflam in patients with
palmoplantar pustulosis were reported by Genmab and Medarex in December 2004.
Fifty-seven percent (16 of 28) of patients who completed the study achieved a
50% or more reduction in disease activity at week 8. In a pooled analysis of
all dose groups after 8 weeks, a statistically significant reduction in
disease activity of 56% was seen. In addition to effectively reducing disease
activity in study patients, HuMax-Inflam was also effective at inhibiting
neutrophil chemotaxis in fluids sampled from patients and the concentration
of HuMax-Inflam in such fluids increased in parallel with higher treatment
doses.

Conference Call Genmab will hold a conference call about the news today,
    Thursday September 13, 2007 at:

    3:00 PM CEST 2:00 PM BST 9:00 AM EDT

    The dial in numbers are as follows:

    (+1)-800-289-0533 (in the US) 
    +1-913-981-5525 (outside the US)

    The conference call will be held in English.

    A live webcast of the call will be available at http://www.genmab.com. 
    The webcast will also be archived on Genmab's website.



About Genmab A/S

Genmab is a leading international biotechnology company
focused on developing fully human antibody therapeutics for unmet medical
needs. Using unique, cutting-edge antibody technology, Genmab's world class
discovery and development teams have created and developed an extensive
pipeline of products for potential treatment of a variety of diseases
including cancer and autoimmune disorders. As Genmab advances towards a
commercial future, we remain committed to our primary goal of improving the
lives of patients who are in urgent need of new treatment options. For more
information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM);
HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all
trademarks of Genmab A/S.